WebProgression-free survival ( PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". … WebApr 10, 2024 · Primary results from the study were released in 2016 and suggested a progression-free survival benefit for the niraparib arm compared to the placebo arm. …
Overall Survival in KEYNOTE-177: Pembrolizumab vs ... - ASCO …
WebApr 9, 2024 · Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan–Meier method with a log-rank test. The cumulative incidence of … WebFeb 1, 2024 · Keytruda (pembrolizumab) continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer (NSCLC) after more than five years of follow-up, according to results from the phase 2/3 … reclaim ohio
Progression-free survival as a surrogate for overall survival in ...
WebJun 1, 2024 · Greater bone involvement curbs survival after radioligand prostate cancer therapy SNPs show predictive value for prostate cancer Key clinical point: Overall survival among men with castration sensitive prostate cancer was similar whether they were treated with docetaxel or abiraterone, but progression-free survival favored abiraterone patients. WebDec 10, 2024 · Drug, indication, and clinical trial characteristics are described. Hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), and relative risk for … WebApr 22, 2024 · The co-primary endpoints were overall survival and progression-free survival in the intention-to-treat population. Major Findings. Median follow-up for the final overall survival analysis was 44.5 months (interquartile range = 39.7–49.8 months). A total of 93 patients (60%) crossed over from chemotherapy to anti–PD-1 or anti–PD-L1 therapy ... reclaim old twitter account